Evaluation of the impact of anaemia on quality of life among breast cancer patients undergoing chemotherapy in Malaysia (original) (raw)
Related papers
2021
Purpose This study aimed to assess the level of anaemia severity, evaluate the current treatment practice of anaemia, and to determine the association between anaemia level and its management on quality of life of breast cancer patients in Malaysia. Methods A prospective study design was conducted among breast cancer patients in multicancer centers in Malaysia including three follow ups. Clinical data were collected from their medical records and at each follow up, they were required to fill in a functional assessment chronic therapy (FACT-An) questionnaire. Descriptive and inferential statistical analysis were done using SPSS. Results Out of 120 participants, 32% received anaemia treatment. Out of 32% who received anti-anaemic medication, the majority of patients (87%) were prescribed with iron supplementation and only 13% received combination of blood transfusion and iron therapy and no one received erythropoietin stimulating agents (ESAs). Findings reported that the curve of the ...
2021
Objectives: The purpose of this study was to determine the association between anaemia severity and risk factors among breast cancer patients. Methods: A prospective study design was conducted in three different oncology centres in Malaysia where 120 anaemic breast cancer patients (haemoglobin < 12 g/dL) were identified through medical chart review. Patients were followed-up for three cycles of chemotherapy and data such as haemoglobin (Hb) levels and demographic or clinical data were also recorded on each follow-up. Data were analysed using SPSS. Results: The average mean of Hb level of all follow-ups was 10.34 ± 0.73 g/dL. A chi-square and multiple logistic regression analysis revealed a significant strong association between anaemia severity and associated risk factors, i.e., demographic data (age, body mass index [BMI], and marital status), chemotherapy data (dose delay, number of regimens, and type of chemotherapy), and cancer stage. Conclusion: Factors that have a great imp...
Proceedings of Malikussaleh International Conference on Health and Disaster Medicine (MICOHEDMED)
Introduction: Chemotherapy is the most common treatment before and after surgery to treat breast cancer patients, anaemia is the most common side effect of chemotherapy, and transfusion is the most common side effect of chemotherapy treatment. The increase in the haemoglobin levels can be achieved quickly, but the side effects that may occur are also not small. This study aims to determine the relationship between chemotherapy and the incidence of anaemia in breast cancer patients at the Cut Meutia General Hospital, North Aceh Methods: The type of research is analytical, and the method uses a cross-sectional design carried out from October 2021 to March 2022. A total sample of 45 breast cancer patients was taken by total sampling that met the inclusion and exclusion criteria. Results: The results showed that there were 15 people (16.00) of chemotherapy drugs using the platinum base and antrasiklin for 30 people (26.50). Man Whitney test results obtained p <0.007 indicates that th...
Proceedings of the 3rd International Conference on Sport Science, Health, and Physical Education (ICSSHPE 2018), 2019
The prevalence of breast cancer at Dr. Moewardi Hospital is currently ranked first on oncology cases at 18.92%. Chemotherapy is effective in fighting cancer cells, reducing tumor size, and giving a good prognosis in patients. Side effects of chemotherapy are indigestion with a manifestation of decreased food intake which has an impact on nutritional status and hemoglobin levels. Risk factors causing anemia are chemotherapy cycle, body mass index (BMI), age and initial hemoglobin. Objective: To determine the predictive factors of anemia caused by chemotherapy. Method: observational with cross sectional design. Subjects of the study were 115 patients aged 30-60 years who were taken randomly. Multivariate analysis with logistic regression to find the basic risk factors for anemia. Results: Anemia prevalence was 87%. The occurrence of anemia was significantly associated with four risk factors: Chemotherapy cycle (OR=0.282; 95% CI=0.078-1.015;p=0.053), BMI (OR = 7.544; 95% CI=0.962-59.174;p=0.054), Age (OR=0.925; 95% CI=0.396-2.180;p=0.865), Hb at baseline (OR=2.0; 95% CI=1.539-2.599;p=0.001). Conclusion: Identification of chemotherapy risk factors such as chemotherapy cycles, age, BMI, and Hb levels are important for patients at risk for anemia. These risk factors Hb at baseline are significantly associated with anemia in chemotherapy patients.
Cancer management and research, 2016
To assess hemoglobin (Hb) outcomes and fatigue-related quality-of-life (QoL) (electronic assessment) in patients with solid tumors and symptomatic chemotherapy-induced anemia receiving cytotoxic chemotherapy and darbepoetin alfa (DA) or another erythropoiesis-stimulating agent according to European indication. eAQUA was a Phase IV prospective observational study. The primary outcome (assessed in the primary analysis set [PAS]: patients receiving one or more DA dose who had baseline and week 9 assessments for Hb and QoL) was the proportion of patients receiving DA having both Hb increases ≥1 g/dL and improved QoL between baseline and week 9. Functional Assessment of Cancer Therapy-Fatigue (FACT-F) subscale scores were anchored to fatigue visual analog scale scores to determine the minimally important difference for improved QoL. Overall data/data over time are reported for the full analysis set (patients receiving one or more erythropoiesis-stimulating agent dose, n=1,158); week 9 da...
2009
Anemia is one of the most important key factors affecting the quality of life (QOL) which needs addressing, as it is an important domain in optimal QOL. About 60-75% of the cancer patients invariably developed anemia most of them were at advanced stages where treatment options were limited and mainly palliative. In advanced stages of cancer, QOL issues become an integral part of decision-making about various treatment options. Several key factors, including age, gender, co-morbidities, and quality of supportive care affects QOL in patients suffering from neoplasia. Fatigue appeared to exert adverse effect and impact on survival and QOL. Among the wide range of cancers anemia was most prevalent in hematological malignancies, followed by breast cancer, stomach, head and neck cancers. The probable causes that relate to various therapeutic protocols were dealt-with individually along with management strategies. In this study, we have evaluated severity of anemia for the first time in ca...
European Journal of Cancer, 2004
The European Cancer Anaemia Survey (ECAS) was conducted to prospectively evaluate the prevalence, incidence and treatment of anaemia (haemoglobin <12.0 g/dL) in European cancer patients, including the relationship of mild, moderate and severe anaemia to performance status. Patients were evaluated for up to 6 months. Data (N = 15 367) included demographics, tumour type, performance status, haemoglobin levels, cancer treatments and anaemia treatments. Prevalence of anaemia at enrollment was 39.3% (haemoglobin <10.0 g/dL, 10%), and 67.0% during the survey (haemoglobin <10.0 g/dL, 39.3%). Low haemoglobin levels correlated significantly with poor performance status. Incidence of anaemia was 53.7% (haemoglobin <10.0 g/dL, 15.2%). Anaemia was treated in 38.9% of patients (epoetin, 17.4%; transfusion, 14.9%; and iron, 6.5%). Mean haemoglobin to initiate anaemia treatment was 9.7 g/dL. Anaemia prevalence and incidence in cancer patients are high. Anaemia significantly correlates with poor performance status and many anaemic patients are not treated.
Cancers
Anemia is a common condition in cancer patients and is associated with a wide variety of symptoms that impair quality of life (QoL). However, exactly how anemia affects QoL in cancer patients is unclear because of the inconsistencies in its definition in previous reports. We aimed to examine the clinical impact of anemia on the QoL of cancer patients using specific questionnaires. We performed a post-hoc analysis of a multicenter, prospective, case-control study. We included patients with cancer with (cases) or without (controls) anemia. Participants completed the European Organization for Research and Treatment of Cancer Quality of Life questionnaire version 3.0 (EORTC QLQ-C30) and Euro QoL 5-dimension 3-level (EQ–5D–3L) questionnaire. Statistically significant and clinically relevant differences in the global health status were examined. From 2015 to 2018, 365 patients were included (90 cases and 275 controls). We found minimally important differences in global health status accor...
Frequency of Chemotherapy Induced Anemia in Breast Cancer Patients
Iranian Journal of Cancer Prevention, 2016
Background: Breast cancer is the second most common malignancy in women, worldwide. Several etiologic factors may cause anemia in a patient with breast cancer. Anemia is a prevalent complication in patients with breast cancer who undergo chemotherapy which affects the health status and quality of life in these patients. The aim of this study was to evaluate the prevalence of anemia in patients with non-metastatic breast cancer who underwent adjuvant chemotherapy. Methods: In this cross-sectional study, 144 women with non-metastatic breast cancer who referred to radiotherapy and oncology department of Imam Reza hospital and met inclusion criteria were included. Data were obtained from patients' archived documents and were analyzed by SPSS software (version16). Results: In this study, 41% of patients were anemic before the chemotherapy and 43.1% of patients became anemic during and after treatment. The prevalence of post-chemotherapy anemia was significantly higher in advanced stages of cancer (P = 0.01). The chance of developing anemia were more in patients who underwent 8 cycles and AC + paclitaxel regimen, compared to the ones with 6 cycles and other regimens. There was no significant relationship between the prevalence of anemia and type of chemotherapy regimen, number of chemotherapy cycles, positive lymph nodes, co-morbidities, menstrual status, and body mass index (BMI). Conclusions: Due to the high prevalence of chemotherapy-induced anemia and its effects on quality of life, even mild degrees of anemia should be detected and evaluated before treatment. Considering early interventions is of cardinal importance, especially in the elderly.
European Journal of Cancer Care, 2010
A prospective observational study of anaemia management in cancer patients-results from the German Cancer Anaemia Registry The use of erythropoiesis-stimulating agents (ESA) in cancer patients is still under debate. However, little is known about rationales, strategies, objectives, and effectiveness of anaemia treatments in common practice. The Cancer Anaemia Registry prospectively surveyed about 2000 cancer patients with anaemia throughout Germany. The main objectives of anaemia treatment regardless of modality were to improve quality of life (QOL) and to correct haemoglobin (Hb) levels. The Hb threshold for any anaemia treatment (means Ϯ SD: 9.4 Ϯ 1.2 g/dL) but not for blood transfusions (8.7 Ϯ 1.0 g/dL) depended on cancer type and treatment strategy. Physicians preferred ESA as first-line treatment to prevent transfusions in patients with solid tumours, if they thought that chemotherapy caused the anaemia. If they suspected other causes or patients had lymphoproliferative malignancies, physicians preferred transfusions or attempted to correct underlying disorders; both mainly to improve QOL or prognosis. Effectiveness of all strategies was comparable. However, ESA most effectively prevented transfusions; primary transfusions appeared less suitable for correcting Hb or improving QOL. Using supportive treatments for QOL improvement was common whereas diagnostic measures and intravenous iron therapy were underused. Prospective clinical trials using QOL as end point and evaluating diagnostics in cancer-associated anaemia are warranted.